News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Actelion Ltd. Board Nominees Deny Sale is Main Aim
April 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - A group of prospective Actelion board members denied speculation they planned to prepare Europe's biggest biotech for sale and said they wanted instead to overhaul it.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Deals
Lilly Doubles Down on Insilico’s AI Medicines, Bets Up to $2.75B
March 30, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Novartis Keeps Deals Coming With $2B Excellergy Takeover
March 27, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
March 25, 2026
·
3 min read
·
Tristan Manalac
Mergers & acquisitions
Gilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos
March 24, 2026
·
3 min read
·
Tristan Manalac
